The team behind the Texas Cancer Interception Institute
Form Title
Ronan Kelly, MD, MBA, FASCO, has over 20 years of experience in medical oncology, dedicating his career to groundbreaking research. With more than 200 peer-reviewed publications, he has led international studies published in the New England Journal of Medicine, Nature Medicine and the Journal of Clinical Oncology. Dr. Kelly is deeply committed to delivering compassionate care and finding breakthroughs in cancer research to improve people’s lives.
From Dr. Kelly
Data proves that early detection of cancer increases the chances of a full recovery, yet only 28% of cancers have a recommended routine screening test—making cancer the second-leading cause of death in the U.S. Today, we're working to change that.
A new era in cancer detection
The Texas Cancer Interception Institute aims to improve cancer care with a strong focus on early detection, using advanced technology and emerging AI tools to detect cancer earlier than ever.
With greater awareness about your cancer risk, you can take proactive steps to protect yourself and intercept cancer before it advances.
At the Texas Cancer Interception Institute, advancements in artificial intelligence, the study of biological factors known as “multiomics” and population medicine, can transform the way cancer is detected and treated.
Artificial Intelligence (AI):
AI-driven technologies can analyze medical data to identify patterns that may indicate early signs of cancer. From advanced imaging interpretation to predictive analytics, AI tools will enable us to create a future of precision oncology, speeding up diagnosis and allowing for earlier and more effective interventions.
Multiomics:
By understanding the genetic characteristics of cancer, we can identify people at higher risk of developing the condition, personalize their prevention strategies and develop targeted treatments to potentially improve their outcomes—all while avoiding any unnecessary procedures.
Population Medicine:
By studying health trends across diverse populations, we can identify risk factors, improve access to screenings, create virtual cancer journeys on the MyBSWHealth app and tailor prevention strategies to reach more people—especially those in underserved communities.
Personally, I’ve never been more optimistic than I am right now about our ability to intercept and detect cancer early.
The National Cancer Plan’s Initiative has set out to cut the cancer mortality rate in half over the next 25 years, and the Texas Cancer Interception Institute was founded to drive this effort. By using proactive smartphone technology and AI digital tools, we can empower people to take charge of when and where they screen for cancer.
Ronan Kelly, MD, MBA, FASCO
Director, Charles A. Sammons Cancer Center at Baylor University Medical Center – Dallas
Chief of Oncology, Baylor Scott & White Health – North Texas
Learn how Baylor Scott & White is driving innovation in the future of early cancer detection
